GSK, attempting to stage Blenrep comeback, bids adieu to combo studies with SpringWorks' Ogsiveo

Despite the recent approval of SpringWorks Therapeutics’ Ogsiveo, GSK is calling it quits on prior plans to wed the Pfizer spinout’s drug with its withdrawn cancer med Blenrep.

SpringWorks on Thursday received a notice of termination on the partners’ amended collaboration and licensing deal, which was struck on Sept. 6, 2022, according to a Friday securities filing.